Jonas W Bartstra1, Fieke Draaisma1, Sabine R Zwakenberg2, Nikolas Lessmann3, Jelmer M Wolterink4, Yvonne T van der Schouw2, Pim A de Jong1, Joline W J Beulens5. 1. Department of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 3. Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands. 4. Department of Applied Mathematics, Technical Medical Centre, University of Twente, Enschede, The Netherlands. 5. Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Location VUmc, Amsterdam Public Health and Amsterdam Cardiovascular Sciences Research Institutes, Postbox 7057, 1007 MB, Amsterdam, The Netherlands. j.beulens@amsterdamumc.nl.
Abstract
PURPOSE: Vitamin K-dependent proteins are involved in (patho)physiological calcification of the vasculature and the bones. Type 2 diabetes mellitus (DM2) is associated with increased arterial calcification and increased fractures. This study investigates the effect of 6 months vitamin K2 supplementation on systemic arterial calcification and bone mineral density (BMD) in DM2 patients with a history of cardiovascular disease (CVD). METHODS: In this pre-specified, post hoc analysis of a double-blind, randomized, controlled clinical trial, patients with DM2 and CVD were randomized to a daily, oral dose of 360 µg vitamin K2 or placebo for 6 months. CT scans were made at baseline and follow-up. Arterial calcification mass was quantified in several large arterial beds and a total arterial calcification mass score was calculated. BMD was assessed in all non-fractured thoracic and lumbar vertebrae. RESULTS: 68 participants were randomized, 35 to vitamin K2 (33 completed follow-up) and 33 to placebo (27 completed follow-up). The vitamin K group had higher arterial calcification mass at baseline [median (IQR): 1694 (812-3584) vs 1182 (235-2445)] for the total arterial calcification mass). Six months vitamin K supplementation did not reduce arterial calcification progression (β [95% CI]: - 0.02 [- 0.10; 0.06] for the total arterial calcification mass) or slow BMD decline (β [95% CI]: - 2.06 [- 11.26; 7.30] Hounsfield units for all vertebrae) when compared to placebo. CONCLUSION: Six months vitamin K supplementation did not halt progression of arterial calcification or decline of BMD in patients with DM2 and CVD. Future clinical trials may want to pre-select patients with very low vitamin K status and longer follow-up time might be warranted. This trial was registered at clinicaltrials.gov as NCT02839044.
PURPOSE: Vitamin K-dependent proteins are involved in (patho)physiological calcification of the vasculature and the bones. Type 2 diabetes mellitus (DM2) is associated with increased arterial calcification and increased fractures. This study investigates the effect of 6 months vitamin K2 supplementation on systemic arterial calcification and bone mineral density (BMD) in DM2 patients with a history of cardiovascular disease (CVD). METHODS: In this pre-specified, post hoc analysis of a double-blind, randomized, controlled clinical trial, patients with DM2 and CVD were randomized to a daily, oral dose of 360 µg vitamin K2 or placebo for 6 months. CT scans were made at baseline and follow-up. Arterial calcification mass was quantified in several large arterial beds and a total arterial calcification mass score was calculated. BMD was assessed in all non-fractured thoracic and lumbar vertebrae. RESULTS: 68 participants were randomized, 35 to vitamin K2 (33 completed follow-up) and 33 to placebo (27 completed follow-up). The vitamin K group had higher arterial calcification mass at baseline [median (IQR): 1694 (812-3584) vs 1182 (235-2445)] for the total arterial calcification mass). Six months vitamin K supplementation did not reduce arterial calcification progression (β [95% CI]: - 0.02 [- 0.10; 0.06] for the total arterial calcification mass) or slow BMD decline (β [95% CI]: - 2.06 [- 11.26; 7.30] Hounsfield units for all vertebrae) when compared to placebo. CONCLUSION: Six months vitamin K supplementation did not halt progression of arterial calcification or decline of BMD in patients with DM2 and CVD. Future clinical trials may want to pre-select patients with very low vitamin K status and longer follow-up time might be warranted. This trial was registered at clinicaltrials.gov as NCT02839044.
Entities:
Keywords:
Arterial calcification; Bone mineral density; Cardiovascular disease; Randomized controlled clinical trial; Type 2 diabetes; Vitamin K
Authors: Anthony G Mansour; Essa Hariri; Yazan Daaboul; Serge Korjian; Andrew El Alam; Athanase D Protogerou; Hala Kilany; Albert Karam; Antoine Stephan; Sola Aoun Bahous Journal: J Am Soc Hypertens Date: 2017-07-13
Authors: A Mott; T Bradley; K Wright; E S Cockayne; M J Shearer; J Adamson; S A Lanham-New; D J Torgerson Journal: Osteoporos Int Date: 2019-05-10 Impact factor: 4.507
Authors: Caroline K Kramer; Bernard Zinman; Jorge L Gross; Luis H Canani; Ticiana C Rodrigues; Mirela J Azevedo; Ravi Retnakaran Journal: BMJ Date: 2013-03-25
Authors: Maurice Halder; Ploingarm Petsophonsakul; Asim Cengiz Akbulut; Angelina Pavlic; Frode Bohan; Eric Anderson; Katarzyna Maresz; Rafael Kramann; Leon Schurgers Journal: Int J Mol Sci Date: 2019-02-19 Impact factor: 5.923
Authors: Essa Hariri; Nicholas Kassis; Jean-Pierre Iskandar; Leon J Schurgers; Anas Saad; Omar Abdelfattah; Agam Bansal; Toshiaki Isogai; Serge C Harb; Samir Kapadia Journal: Open Heart Date: 2021-11